Head-to-head · Cost-Efficiency Index
LevelsRx vs StackMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LevelsRx
Shoppers who want a LegitScript-verified option with low headline starting prices.
Visit LevelsRxStackMD
Shoppers price-scanning for the lowest advertised entry point, who should confirm true dose-adjusted cost before signing up.
Visit StackMDThe verdict
LevelsRx and StackMD tie on the Cost-Efficiency Index at 60/100, so neither wins outright on the numbers. For most shoppers we'd start with LevelsRx (ranked #251, a hair above #257) — Shoppers who want a LegitScript-verified option with low headline starting prices. But StackMD is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LevelsRx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LevelsRx | StackMD |
|---|---|---|
| Cost-Efficiency Index | 60/100 | 60/100 |
| Semaglutide / mo | $150/mo (all doses, compounded oral) | Not disclosed |
| Tirzepatide / mo | $240/mo (starting dose, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $1,800 | — |
| Tirzepatide / yr (modeled) | $2,880 | — |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #251 | #257 |
LevelsRx
60/100Where the value is
- Genuine, verifiable LegitScript certification badge
- Offers injectable semaglutide, oral/liquid semaglutide, and tirzepatide
- Low headline starting prices
The tradeoffs
- No dose-tier pricing table published
- No named compounding pharmacy partner
StackMD
60/100Where the value is
- Low advertised entry price ($99/mo) for both semaglutide and tirzepatide
- Clear FDA-compounding disclaimer shown up front
- Distinct national telehealth brand (separate from the similarly-named Long Island clinic)
The tradeoffs
- Identical $99 headline for both drugs strongly suggests a lowest-dose teaser, not full treatment pricing
- No dose tiers, medical director, pharmacy name, states list, or LegitScript status could be confirmed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.